Improvement of stunned myocardium in dogs with olmesartan, an angiotensin II type 1 receptor antagonist, is independent of type 2 receptors

Pharmacology

Volumn 82, Issue 1, 2008, Pages 22-29

  Kano, Seiichiro ^a   Satoh, Kumi ^a   Kaneta, Shigeru ^a   Ichihara, Kazuo ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Angiotensin; Contractile force; Dog myocardium; Ischemia reperfusion

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; OLMESARTAN; PENTOBARBITAL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOG; DOSE RESPONSE; DRUG MECHANISM; GENE EXPRESSION; HEART CONTRACTION; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; NONHUMAN; PRIORITY JOURNAL; STUNNED HEART MUSCLE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DOGS; FEMALE; HEMODYNAMICS; IMIDAZOLES; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL STUNNING; MYOCARDIUM; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 2; TETRAZOLES;

EID: 46449128402     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127364     Document Type: Article

References (25)

1. Fukutomi T, Satoh K, Ogoshi S, Ichihara K: Effects of pimobendan and EGIS 9377, cardiotonic agents, and OG-VI, a nucleosidenucleotide mixture, administered during reperfusion after ischemia on stunned myocardium in dogs. Coron Artery Dis 2000;11:83-90.
2. Opie LH, Sack MN: Enhanced angiotensin II activity in heart failure. Reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res 2001;88:654-658.
3. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD: Angiotensin II receptors and angiotensin II receptors antagonists. Pharmacol Rev 1993;45:205-251.
4. Horiuchi M, Akishita M, Dzau VJ: Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-621.
5. 2, judgment day. Which angiotensin receptor is the culprit in cardiac hypertrophy? Circulation 2001;104:247-248.
6. Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, Koike H: Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995;285:181-188.
7. Robertson JIS, Tillman DM: Converting enzyme inhibitors in the treatment of hypertension. J Cardiovasc Pharmacol 1987;10(suppl 7):S43-S48.
8. Packer M: Converting enzyme inhibition in the management of severe chronic congestive heart failure: physiologic concept. J Cardiovasc Pharmacol 1987;10(suppl 7):S83-S87.
9. Izumi H, Nakai T, Kano S, Hoshi K, Ichihara K: Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs. Coron Artery Dis 1996;7:775-779.
10. Nakai T, Satoh K, Kosugi T, Hoshi K, Ichihara K: Participation of angiotensin II and bradykinin in contractile function in dog stunned myocardium. Eur J Pharmacol 1999;382:187-196.
11. Liu Y-H, Yang X-P, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA: Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest 1997;99:1926-1935.
12. 2 subtype-specific angiotensin II ligands. J Pharmacol Exp Ther 1992;262:1154-1160.
13. Ichihara K, Abiko Y: Difference between endocardial and epicardial utilization of glycogen in the ischemic heart. Am J Physiol 1975;229:1585-1589.
14. Bergmeyer H-U: Methods of Enzymatic Analysis. New York, Academic Press, 1974, pp 1984-1985.
15. Nakai T, Kano S, Satoh K, Hoshi K, Ichihara K: Effects of adenine nucleotide analogues on myocardial dysfunction during reperfusion after ischemia in dogs. J Cardiovasc Pharmacol 1996;28:264-270.
16. Satoh K, Ichihara K: Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol 2000;35:256-262.
17. 2+-dependent signaling. Circ Res 1995;76:1-15.
18. Jennings RB, Schaper J, Hill ML, Steenbergen C Jr, Reimer KA: Effect of reperfusion late in the phase of reversible ischemic injury. Changes in cell volume, electrolytes, metabolites, and ultrastructure. Circ Res 1985;56:262-278.
19. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ: Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven transmembrane receptors. J Biol Chem 1993;268:24539-24542.
20. Matsubara H, Kanasaki M, Murasawa S, Tsukaguchi Y, Nio Y, Inada M: Differential gene expression and regulation of angiotensin II receptor subtypes in rat cardiac fibroblasts and cardiomyocytes in culture. J Clin Invest 1994;93:1592-1601.
21. Suzuki J, Matsubara H, Urakami M, Inada M: Rat angiotensin II (type II) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 1993;73:439-447.
22. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M: Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995;95:46-54.
23. 3 receptor and PKCε proteins. J Renin Angiotensin Aldosterone Sys 2000;1:184-195.
24. 2 receptors. J Cardiovasc Pharmacol 2002;39:107-116.
25. Yaoita H, Ogawa K, Maehara K, Maruyama Y: Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998;97:279-281.